Matt Teater

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2114793/publications.pdf

Version: 2024-02-01

35 papers	3,169 citations	304743 22 h-index	454955 30 g-index
35 all docs	35 docs citations	35 times ranked	5390 citing authors

#	Article	IF	Citations
1	Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival. Blood Cancer Discovery, 2022, 3, 50-65.	5.0	14
2	SETD2 Haploinsufficiency Enhances Germinal Centerâ€“Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis. Cancer Discovery, 2022, 12, 1782-1803.	9.4	14
3	Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL. Blood, 2021, 137, 788-800.	1.4	22
4	Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture. Nature, 2021, 589, 299-305.	27.8	155
5	Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence. Cancer Discovery, 2021, 11, 1542-1561.	9.4	133
6	Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes. Blood Advances, 2020, 4, 5226-5231.	5.2	28
7	Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response. Cancer Cell, 2020, 37, 655-673.e11.	16.8	93
8	The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing. Nature Cancer, 2020, 1, 653-664.	13.2	35
9	TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate. Cell, 2020, 182, 297-316.e27.	28.9	63
10	Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. Cancer Discovery, 2020, 10, 440-459.	9.4	103
11	Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. Cancer Discovery, 2019, 9, 546-563.	9.4	213
12	Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML. Cancer Discovery, 2019, 9, 872-889.	9.4	36
13	AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis. Nature Communications, 2018, 9, 222.	12.8	51
14	TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis. Cancer Discovery, 2018, 8, 1632-1653.	9.4	120
15	Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth. Journal of Clinical Investigation, 2018, 128, 4397-4412.	8.2	51
16	Untangling the Web of Lymphoma Somatic Mutations. Cell, 2017, 171, 270-272.	28.9	1
17	EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop. Nature Communications, 2017, 8, 877.	12.8	132
18	Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma. Science Translational Medicine, 2017, 9, .	12.4	52

#	Article	IF	Citations
19	CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. Cancer Discovery, 2017, 7, 38-53.	9.4	218
20	EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. Cancer Cell, 2016, 30, 197-213.	16.8	200
21	Multi-tiered Reorganization of the Genome during B Cell Affinity Maturation Anchored by a Germinal Center-Specific Locus Control Region. Immunity, 2016, 45, 497-512.	14.3	112
22	Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". Nature Medicine, 2016, 22, 578-579.	30.7	7
23	AICDA Introduces Epigenetic Plasticity in Germinal Center-Derived Lymphomas and Accelerates Lymphomagenesis. Blood, 2016, 128, 1045-1045.	1.4	1
24	Acute Myeloid Leukemia Cells Resist Chemotherapy through a Reversible Senescence-like State Maintaining Repopulation Potential. Blood, 2016, 128, 582-582.	1.4	1
25	Crebbp Mutations Disrupt Dynamic Enhancer Acetylation in B-Cells, Enabling HDAC3 to Drive Lymphomagenesis. Blood, 2016, 128, 735-735.	1.4	0
26	Cooperative Gene Repression By DNA Methylation and LSD1-Mediated Enhancer Inactivation in Acute Myeloid Leukemia. Blood, 2016, 128, 1048-1048.	1.4	0
27	Loss of BAP1 function leads to EZH2-dependent transformation. Nature Medicine, 2015, 21, 1344-1349.	30.7	297
28	DNA Methylation Dynamics of Germinal Center B Cells Are Mediated by AID. Cell Reports, 2015, 12, 2086-2098.	6.4	87
29	A Chromatin Reader That Acts As a Key to Lock in and Coordinate Recruitment of Transcription Factors and a Novel Polycomb Complex to Bivalent Chromatin Thus Driving Formation of Germinal Centers and B-Cell Lymphomas. Blood, 2015, 126, 434-434.	1.4	0
30	BAP1 Loss Results in EZH2-Dependent Transformation in Myelodysplastic Syndromes. Blood, 2015, 126, 713-713.	1.4	0
31	The BCL6 RD2 Domain Governs Commitment of Activated B Cells to Form Germinal Centers. Cell Reports, 2014, 8, 1497-1508.	6.4	67
32	CTCF Haploinsufficiency Destabilizes DNA Methylation and Predisposes to Cancer. Cell Reports, 2014, 7, 1020-1029.	6.4	154
33	Demethylase Activity of Aid during Germinal Center B Cell Maturation Could Contribute to Lymphomagenesis. Blood, 2014, 124, 59-59.	1.4	1
34	EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation. Cancer Cell, 2013, 23, 677-692.	16.8	706
35	BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL. Cancer Discovery, 0, , OF1-OF20.	9.4	2